Investigating the effectiveness of Metarrestin as a perinucleolar compartment inhibitor to suppress metastasis
Session Number
Project ID: MEDH 07
Advisor(s)
Dr. Sui Huang, Northwestern University Feinberg School of Medicine
Discipline
Medical and Health Sciences
Start Date
20-4-2022 10:05 AM
End Date
20-4-2022 10:20 AM
Abstract
Cancer is a leading cause of death worldwide and the second leading cause of death in the United States, and the primary cause of mortality is metastasis to other organs. The perinucleolar compartment (PNC) is a sub-nucleolar structure that has been associated with metastasis and the progression of cancer, resulting in poor patient outcomes. To combat metastatic cancer, look towards the drug metarrestin. Metarrestin disrupts the nucleolar structure by inhibiting these perinucleolar compartments, and could potentially be a therapeutic treatment of metastatic cancer. Continuing previous research on the effectiveness of metarrestin as a drug to suppress metastasis, we analyzed the effectiveness of derivatives of metarrestin in inhibiting PNCs by tagging PNCs with antibodies using immunofluorescence. Additionally, looking at soft agar compounds, we have been able to mimic tissue cells and how metarrestin treatment affects tumor cell growth.
Investigating the effectiveness of Metarrestin as a perinucleolar compartment inhibitor to suppress metastasis
Cancer is a leading cause of death worldwide and the second leading cause of death in the United States, and the primary cause of mortality is metastasis to other organs. The perinucleolar compartment (PNC) is a sub-nucleolar structure that has been associated with metastasis and the progression of cancer, resulting in poor patient outcomes. To combat metastatic cancer, look towards the drug metarrestin. Metarrestin disrupts the nucleolar structure by inhibiting these perinucleolar compartments, and could potentially be a therapeutic treatment of metastatic cancer. Continuing previous research on the effectiveness of metarrestin as a drug to suppress metastasis, we analyzed the effectiveness of derivatives of metarrestin in inhibiting PNCs by tagging PNCs with antibodies using immunofluorescence. Additionally, looking at soft agar compounds, we have been able to mimic tissue cells and how metarrestin treatment affects tumor cell growth.